Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06367816 |
Other study ID # |
13509 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
April 11, 2024 |
Est. completion date |
December 31, 2024 |
Study information
Verified date |
April 2024 |
Source |
University of Genova |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Thus far, the closed-loop ventilation mode INTELLiVENT-ASV has been extensively tested in
various groups of critically ill patients, and has been shown to be effective and safe in
various groups of ventilated patients, including those at risk of acute respiratory distress
syndrome (ARDS), patients with ARDS, and patients with chronic obstructive pulmonary disease
(COPD). Some of these studies included acute brain injury (ABI) patients, but the
effectiveness, efficacy and safety of INTELLiVENT-ASV has never been thoroughly tested in
these patients. The current study will investigate the effectiveness in providing both brain-
and lung protective ventilation, the safety and the efficacy of a closed-loop ventilation
mode (INTELLiVENT-ASV) in acute brain injury patients, using breath-by-breath data.
Description:
Rationale: Closed-loop ventilation has been proven effective in lung-protective ventilation
but its effectiveness, safety and efficacy in providing both lung- and brain-protective
ventilation in patients with acute brain injury has not been investigated.
Objective: To evaluate the effectiveness, efficacy and safety of INTELLiVENT-ASV with respect
to brain- and lung-protective ventilation in ABI patients
Hypothesis: We hypothesize that INTELLiVENT-ASV is effective with regard to brain- and
lung-protective ventilation (that is achieving brain- and lung- protective targets),
efficacious (that is improving outcomes), and that INTELLiVENT-ASV is safe in invasively
ventilated ABI patients.
Study design: Single-center, crossover trial.
Methods: In this prospective observational study, breath-by-breath ventilation data will be
available from before and after the switch to closed-loop ventilation with INTELLiVENT-ASV,
wherein the decision to switch is determined by the attending healthcare worker, i.e., not
protocolized and only for clinical/organizational reasons. High granular data are collected
both before and after this switch, limited to three hours for conventional and three hours
for closed-loop ventilation. Neuromonitoring is part of current clinical practice and data
will be collected only when available.
Study population: Invasively ventilated patients diagnosed with acute brain injury Methods:
When the ventilator is switched upon the caregivers decision, data will be collected from
three hours before the switch and three hours after the switch.
Study endpoints: The primary composite endpoint is the proportion of breaths and proportion
of time within predefined zones of ventilation (based on VT and airway pressures, saturation
of peripheral O2 (SpO2) and end-tidal CO2 (EtCO2).